09:17 AM EST, 03/08/2024 (MT Newswires) -- Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF ( IBB ) was inactive and the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% recently.

Amylyx Pharmaceuticals ( AMLX ) was retreating by over 82% after saying its phase 3 clinical trial evaluating AMX0035 in patients with amyotrophic lateral sclerosis, or ALS, failed to meet the primary and secondary endpoints at week 48.

Kyverna Therapeutics ( KYTX ) was up more than 2% after saying it has formed a collaboration with Stanford University to allow the use of the company's KYV-101 investigational therapy for multiple sclerosis in a phase 1 investigator-initiated trial.

Evolus ( EOLS ) was down over 4% after its Q4 revenue rose to $61 million from $43.6 million a year earlier but narrowly missed the $61.1 million consensus from analysts surveyed by Capital IQ.